Showing results (61-70 of 68) with videos related to
Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 68 results.
Journal of Medicinal Chemistry|January 29, 2019
Identification and Optimization of Novel Small c-Abl Kinase Activators Using Fragment and HTS MethodologiesGraham L Simpson, Sophie M Bertrand, Jennifer A Borthwick, et al.Communications Biology|March 22, 2020
Extended pharmacodynamic responses observed upon PROTAC-mediated degradation of RIPK2Alina Mares, Afjal H Miah, Ian E D Smith, et al.The Journal of Biological Chemistry|July 18, 2021
GSK137, a potent small-molecule BCL6 inhibitor with in vivo activity, suppresses antibody responses in miceAndrew C Pearce, Mark J Bamford, Ruth Barber, et al.Trauma Surgery & Acute Care Open|August 20, 2025
Does mean arterial pressure augmentation improve neurological recovery of blunt spinal cord injuries: an EAST multicenter trialAimee LaRiccia, Stephanie Doris, Bhairav Shah, et al.ACS Medicinal Chemistry Letters|December 18, 2024
Optimization of Potent and Selective Cyclohexyl Acid ERAP1 Inhibitors Using Structure- and Property-Based Drug DesignRoss P Hryczanek, Andrew S Hackett, Paul Rowland, et al.Journal of Medicinal Chemistry|June 22, 2026
Discovery of an Orally Available Potent ER Aminopeptidase 1 (ERAP1) Inhibitor That Enhances Antitumor Responses and Limits Inflammatory Autoimmunity <i>In Vivo</i>Christopher P Tinworth, Justyna Wojno-Picon, Michael Adam, et al.Bioconjugate Chemistry|February 1, 2021
<i>In Vivo</i> Half-Life Extension of BMP1/TLL Metalloproteinase Inhibitors Using Small-Molecule Human Serum Albumin BindersJulien C Vantourout, Andrew M Mason, Josephine Yuen, et al.Journal of Medicinal Chemistry|April 13, 2026
Automated Molecular Design in BRADSHAW, Applied to the Optimization of ERAP1 InhibitorsRobert P Law, Ian D Wall, Richard Lonsdale, et al.Pageof 7